Type 1: FDA OKs Levemir for Two- to Five-Year-Olds

7550

By: Diabetes Health Staff

The US Food and Drug Administration has approved the use of Novo Nordisk’s Levemir basal insulin for type 1 children aged two to five years. The FDA decision makes Levemir (insulin detemir [rDNA origin]) the only basal insulin approved for use in this age group.
Levemir, introduced to the US market in 2006, was previously approved for older children and adults with type 1 diabetes, as well as insulin-using type 2s.

The new FDA approval was based on Levemir’s performance in reducing the risk of severe hypoglycemic episodes in the two-to-five year age group. Type 1 children in that group who received Levemir and a rapid-acting insulin analog, NovoLog (insulin aspart [rDNA origin] injection), experienced a lower rate of hypoglycemia than those taking NPH and NovoLog. None of the young patients treated with Levemir had a severe hypoglycemic episode, whereas six episodes were reported in three patients treated with NPH over the one-year study period.

Source: Novo Nordisk press release

Comments

comments

Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.